{"abstract": "Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash. The acquisition will make Mylan the world\u2019s third-largest maker of copycat versions of drugs, after Teva Pharmaceuticals of Israel and Novartis of Switzerland.", "web_url": "https://dealbook.nytimes.com/2007/05/14/mylan-labs-in-deal-to-buy-german-generic-drug-unit/", "snippet": "", "lead_paragraph": "Mylan Laboratories has agreed to buy the generic drug unit of Merck, the German drug maker, for 4.9 billion euros ($6.7 billion) in cash. The acquisition will make Mylan the world\u2019s third-largest maker of copycat versions of drugs, after Teva Pharmaceuticals of Israel and Novartis of Switzerland.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Mylan Labs in Deal to Buy German Generic Drug Unit", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-05-14T12:00:41+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c79e226d-c5a7-5f57-b251-c9fe6a13a8cc", "word_count": 114, "uri": "nyt://article/c79e226d-c5a7-5f57-b251-c9fe6a13a8cc"}